Did you know?

Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the closing bid ...See the latest Precision BioSciences Inc stock price (DTIL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Jun 22, 2023 · Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. DURHAM, N.C.--(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel …Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform …Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is ...Nov 24, 2023 · With Precision Biosciences stock trading at $0.41 per share, the total value of Precision Biosciences stock (market capitalization) is $49.24M. Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been ... May 9, 2023 · The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc. Aug 7, 2023 · DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update. Precision BioSciences shares are trading lower after HC Wainwright maintained a Buy rating on the stock but lowered its price target from $5 to $3. Benzinga Newsdesk - Aug 17, 2023, 11:06AMPrecision BioSciences Inc (DTIL) Stock Surges on Promising Performance and Consensus Buy Rating. On July 6, 2023, Precision BioSciences Inc (DTIL) stock experienced a significant increase in its price. The stock had a median target price of $5.00, with a high estimate of $17.00 and a low estimate of $1.00, as projected by six analysts …Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform …The 2030 consensus revenue estimate for Precision Biosciences is $400 million. That feels aggressive but plausible if the company’s pipeline develops and commercializes as expected.Specific Internship opportunities for Summer 2024 will be posted in January 2024. Please check back to our careers site for more specific opportunities then. Our …ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues.Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the closing bid ...Precision BioSciences had revenue of $52.29M in the twelve months ending September 30, 2023, with 150.91% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $13.12M with 78.19% year-over-year growth. In the year 2022, Precision BioSciences had annual revenue of $25.10M, a decrease of -78.28%.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ...Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...In a report released on November 4, Justin Zelin from Precision BioSciences stock soars premarket on R&D Justin Zelin’s Buy rating for the Precision BioSciences stock is based on several factors. The company, which primarily focuses on in-vivo gene editing, is heading towards advancing its ARCUS ... Stock Price Forecast The 4 analysts offering 12-month price 16 thg 8, 2023 ... Precision BioSciences hands global rights to CAR-T candidate; Sagimet closes underwriter's option to buy stock ... Precision BioSciences said ... Tuesday, April 18, 2023. Precision Biosci

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a highly specific ...Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 30, 2023 · The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […] Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina.Precision BioSciences will be entitled to receive an upfront payment of $75 million from NVS. The company is also eligible to receive up to an additional $1.4 billion as future milestone payments ...H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. DURHAM, N.C., March 09, 2023--Precision BioSciences, . Possible cause: Under the terms of the agreement, Precision will receive an upfront cash payment of $100.